Document is current
Any future updates will be listed below
-
Authors
Ota, Mineto https://orcid.org/0000-0003-4552-8573
Spence, Jeffrey P. https://orcid.org/0000-0002-3199-1447
Zeng, Tony https://orcid.org/0000-0002-6509-9879
Dann, Emma https://orcid.org/0000-0002-7400-7438
Milind, Nikhil
Marson, Alexander https://orcid.org/0000-0002-2734-5776
Pritchard, Jonathan K. https://orcid.org/0000-0002-8828-5236
- License Information
-
More Information
Article History
Received: 28 January 2025
Accepted: 5 November 2025
First Online: 10 December 2025
Competing interests
: A.M. is a cofounder of Site Tx, Arsenal Biosciences and Survey Genomics; serves on the boards of directors at Site Tx and Survey Genomics; is a member of the scientific advisory boards of network.bio, Site Tx, Arsenal Biosciences, Cellanome, Survey Genomics, NewLimit, Amgen and Tenaya; owns stock in network.bio, Arsenal Biosciences, Site Tx, Cellanome, NewLimit, Survey Genomics, Tenaya and Lightcast; has received fees from network.bio, Site Tx, Arsenal Biosciences, Cellanome, Spotlight Therapeutics, NewLimit, AbbVie, Gilead, Pfizer, 23andMe, PACT Pharma, Juno Therapeutics, Tenaya, Lightcast, Trizell, Vertex, Merck, Amgen, Genentech, GLG, ClearView Healthcare, AlphaSights, Rupert Case Management, Bernstein and ALDA; is an investor in and informal advisor to Offline Ventures; and is a client of EPIQ. The Marson laboratory has received research support from the Parker Institute for Cancer Immunotherapy, the Emerson Collective, Arc Institute, Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead and Anthem and reagents from Genscript, Illumina and Cellanome. The remaining authors declare no competing interests.
